An Open-Label, Single-Arm, Multicenter Phase 1 Study Evaluating the Safety and Pharmacokinetics of Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma
Phase of Trial: Phase I
Latest Information Update: 08 Feb 2017
At a glance
- Drugs Duvelisib (Primary)
- Indications Lymphoma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 03 Feb 2017 Status changed from active, no longer recruiting to completed.
- 08 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Jan 2017.
- 04 Apr 2016 Planned End Date changed from 1 Nov 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov record.